Breaking News, Collaborations & Alliances

Tetra Bio-Pharma and Dalton Pharma Enter GMP Manufacturing Tie-up

Significant advancement achieved with ARDS-003 sterile injectable nano-emulsion finished drug product.

By: Contract Pharma

Contract Pharma Staff

Tetra Bio-Pharma Inc. has awarded the contract for the manufacturing of its active pharmaceutical ingredient (API), HU-308, and of the intravenous, sterile, finished drug product ARDS-003 to Dalton Pharma Services.   HU-308 is a synthetic small molecule new chemical entity which specifically targets the human CB2 receptors and has the potential to be a new anti-inflammatory drug. Dalton has developed and improved the synthesis process for HU-308. In preparation for moving the clinical program fo...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters